Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Even better!

$Cogent Biosciences (COGT.US)$ Cogent Biosciences (COGT) said Thursday that new lead-in data from ongoing phase 3 trial of a combination of bezuclastinib and sunitinib showed potential to become new standard of care for advanced gastrointestinal stromal tumors, a type of cancer.
The company said the combination treatment led to a disease control rate of 80% in all patients and 100% in patients that were previously treated with imatinib only.
"Coupled with the impressive clinical activity demonstrated by the combination, the addition of bezuclastinib to sunitinib continues to be generally well-tolerated with an encouraging safety profile," Cogent Chief Executive Andrew Robbins said.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
5
Translate
Report
6859 Views
Comment
Sign in to post a comment
3568Followers
23Following
53KVisitors
Follow